Colchicine therapy and the coginitive status of elderly patients with familial Mediterranean fever

Israel Medical Association Journal

Volumn 8, Issue 7, 2006, Pages 469-472

  Leibovitz, Arthur ^a   Lidar, Merav ^b   Baumoehl, Yehuda ^a   Livneh, Avi ^c   Segal, Refael ^a  

^a Tel Aviv University Sackler Faculty of Medicine   (Israel)

^b HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cognitive status; Colchicine; Elderly; Familial Mediterranean fever

Indexed keywords

ACETYLSALICYLIC ACID; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIGOUT AGENT;

AGE; AGED; ARTICLE; BRAIN PROTECTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EDUCATION; FAMILIAL MEDITERRANEAN FEVER; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; OUTPATIENT DEPARTMENT; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEMALE; GERIATRIC ASSESSMENT; MALE;

AGED; CASE-CONTROL STUDIES; COGNITION DISORDERS; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GERIATRIC ASSESSMENT; GOUT SUPPRESSANTS; HUMANS; MALE;

EID: 33746462202     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1988;28:48-59.
2. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis in Familial Mediterranean Fever. N Engl J Med 1986;14:1001-5.
3. Isselbacher KJ, Epstein A. Diverticular, vascular and other disorders of intestine and peritoneum. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's Principles of Internal Medicine. 14th edn. New York: McGraw-Hill, 1998:1654-6.
4. James FF, Dennis WL. Long term memory: disruption by inhibitors of protein synthesis and cytoplasmic flow. Pharmacol Biochem Behav 1981;15:289-96.
5. Walsh TJ, Schulz DW, Tilson HA, Schmechel DE. Colchicine-induced granule cell loss in rat hippocampus: selective behavioral and histological alterations. Brain Res 1986;398:23-36.
6. Veerendra Kumar MH, Gupta YK. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav 2002;73:565-71.
7. Bensimon G, Chermat R. Microtubule disruption and cognitive defects: effect of colchicine on learning behavior in rats. Pharmacol Biochem Behav 1991;38:141-5.
8. Meyers CA, Kudelka AP, Conrad CA, Gelke CK, Grove W, Pazdur R. Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res 1997;3:419-22.
9. Evrard PA, Ragusi C, Boschi G, Verbeeck RK, Scherrmann JM. Simultaneous microdialysis in brain and blood of the mouse: extracellular and intracellular brain colchicine disposition. Brain Res 1998;786:122-7.
10. Flaherty CF, Rowan GA, Emerich DF, Walsh TJ. Effects of intrahippocampal administration of colchicine on incentive contrast and on radial maze performance. Behav Neurosci 1989;103:319-28.
11. Nakayama T, Sawada T. Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacol Biochem Behav 2002; 71:119-38.
12. Livneh A, Langewitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1994;40:1879-85.
13. Ott A, Breteler MMB, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. Br Med J 1995;310:970-3.
14. Tombaugh TN, McIntyre MA. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992;40:922-35.
15. Iverson GL. Interpretation of Mini-Mental State Examination scores in community-dwelling elderly geriatric neuropsychiatry patients. Int J Geriatr Psychiatry 1998;13:661-6.
16. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386-91.
17. Drion N, Risede P, Cholet N, Chanez C, Scherrmann JM. Role of P-170 glycoprotein in colchicine brain uptake. J Neurosci Res 1997;49:80-8.
18. Druley TE, Stein WD, Ruth A, Roninson IB. P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation. Biochemistry 2001;40:4323-31.
19. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996;27:1283-91.
20. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003;305:197-204.
21. Aisen PS, Mann DB, Brickman AM, Santoro J, Fusco M. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:96-101.
22. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:741-9.
23. Dzenko KA, Weltzien RB, Pachter JS. Suppression of A beta-induced monocyte neurotoxicity by anti-inflammatory compounds. J Neuroimmunol 1997;80:6-12
24. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004;23:159-69.